Screener
Amphastar Pharmaceuticals AMPH FR — Non-Current Assets
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NoncurrentAssets.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Net Revenues / Three Months Ended / June 30, 2026 | Net Revenues / Three Months Ended / June 30, 2025 | Net Revenues / Six Months Ended / June 30, 2026 | Net Revenues / Six Months Ended / June 30, 2025 | Long-Lived Assets / June 30, 2026 | Long-Lived Assets / December 31, 2025 |
|---|---|---|---|---|---|---|
| United States | $172,342 | $167,002 | $331,382 | $329,592 | $247,218 | $206,697 |
| China | 4,560 | 299 | 7,042 | 380 | 107,268 | 110,055 |
| France | 7,001 | 7,113 | 16,650 | 14,970 | 34,640 | 36,967 |
| Total | $183,903 | $174,414 | $355,074 | $344,942 | $389,126 | $353,719 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's FR — non-current assets?
- Amphastar Pharmaceuticals (AMPH) reported FR — non-current assets of $34.64M in Q2 2026.
- How has Amphastar Pharmaceuticals's FR — non-current assets changed year-over-year?
- Amphastar Pharmaceuticals's FR — non-current assets decreased by 7.1% year-over-year, from $37.29M to $34.64M.
- What is the long-term trend for Amphastar Pharmaceuticals's FR — non-current assets?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's FR — non-current assets has grown at a -6.4% compound annual growth rate (CAGR), from $190.29M to $146.14M.
- What does FR — non-current assets mean?
- This metric measures the total value of long-term assets, such as property, equipment, and intangible assets, that are specifically allocated to the FR segment. It provides insight into the capital intensity required to support operations within this segment and the scale of long-term investment deployed. Analyzing this helps stakeholders evaluate the asset base supporting the segment's future revenue-generating capacity.
Ask your AI about Amphastar Pharmaceuticals's fr — non-current assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude